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Background: Pimobendan has been shown to impart a significant survival benefit in
cardiomyopathic cats who receive it as part of heart failure therapy. However, use of
pimobendan remains controversial in cats with hypertrophic cardiomyopathy (HCM)
due to lack of pharmacodynamic data for pimobendan in cats with HCM and due to
theoretical concerns for exacerbating left ventricular outflow tract obstructions.
Hypothesis/Objectives: Our objective was to investigate the cardiac effects of
pimobendan in cats with HCM.We hypothesized that pimobendan would not exacerbate
left ventricular outflow tract obstructions and that it would improve echocardiographic
measures of diastolic function.
Animals: Thirteen purpose-bred cats were studied from a research colony with
naturally-occurring HCM due to a variant in myosin binding protein C.
Methods: Cats underwent two examinations 24 h apart with complete standard
echocardiography. On their first day of evaluation, they were randomized to receive oral
placebo or 1.25mg pimobendan 1 h prior to exam. On their second examination, they
were crossed over and received the remaining treatment. Investigators were blinded to
all treatments.
Results: The pimobendan group had a significant increase in left atrial fractional
shortening (pimobendan group 41.7% ± 5.9; placebo group 36.1% ± 6.0; p =
0.04). There was no significant difference in left ventricular outflow tract (LVOT)
velocities between the groups (pimobendan group 2.8 m/s ± 0.8; placebo group
2.6 m/s ± 1.0). There were no significant differences between the number
of cats with LVOT obstructions between groups (12 in pimobendan group; 11
in placebo group; p = 1.00). There were no detectable differences in any
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systolic measures, including left ventricular fractional shortening, mitral annular plane
systolic excursion, and tricuspid annular plane systolic excursion. Doppler-based
diastolic function assessment was precluded by persistent tachycardia.
Conclusions: Improved left atrial function in the pimobendan group could explain some
of the reported survival benefit for HCM cats in CHF. Pimobendan did not exacerbate
LVOT obstructions and thus may not be contraindicated in HCM cats with LVOT
obstructions. Future studies are needed to better characterize other physiologic effects,
particularly regarding diastolic function assessment, and to better assess safety of
pimobendan over a longer time-course.
Keywords: feline, vetmedin, pharmacodynamics, HCM, obstruction, outflow, safety
INTRODUCTION
Pimobendan is a benzimidazole pyridazinone drug that has
shown tremendous benefit in treatment of both canine congestive
heart failure (CHF), pre-clinical dilated cardiomyopathy and
preclinical degenerative valve disease (1–6). Its effects through
calcium sensitization of the cardiac troponin C molecule and
phosphodiesterase III inhibition impart increased inotropy and
balanced vasodilation, leading to improved cardiac output with
greater potency and without documented pro-arrhythmic risk
posed by other inotropic agents, such as digoxin. Its effects have
engendered the term inodilator to describe its actions (1).
The positive effects in prolonging survival times, improving
quality of life, and prolonging time to the development of CHF in
dogs is unequivocal (2–6). However, this benefit is not universally
accepted or characterized in feline cardiac disease. Hypertrophic
cardiomyopathy (HCM) is the most common cardiac disease
in cats, and affects 14.5–14.7% of the domestic cat population
(7, 8). HCM is characterized by concentric hypertrophy of
the left ventricular myocardium and concurrent fibrosis and
stiffening of the heart with a preserved or hyperdynamic systolic
function. The predominant etiology of cardiac decompensation
in these patients is diastolic dysfunction. As a complicating factor,
47.5–67% of HCM cats presenting to referral hospitals have
concurrent left ventricular outflow tract obstructions (LVOTO)
(9, 10). These obstructions can be secondary to several etiologies
including systolic anterior motion of the anterior mitral leaflet
(SAM), asymmetric septal hypertrophy, or a dynamic mid-
ventricular obstruction lesion caused by mid-ventricular and/or
papillary muscle hypertrophy. Cats and humans with HCM
and concurrent LVOTO are termed hypertrophic obstructive
cardiomyopathy. Hypertrophic obstructive cardiomyopathy is
reported as a main cause of symptoms of angina and syncope in
humans with this disease (11, 12). There is concern that a positive
inotrope and afterload reducing drug, such as pimobendan, could
Abbreviations: CHF, Congestive heart failure; HCM, Hypertrophic
cardiomyopathy; HR, Heart Rate; DRVOTO, Right ventricular outflow tract
obstruction; LA, Left atrial; LAFS, Left atrial fractional shortening; LV, Left
ventricle; LVOT, Left ventricular outflow tract; LVOTO, Left ventricular
outflow tract obstruction; M-Mode, Motion-mode echocardiography; RV, Right
ventricle; RVOT, Right ventricular outflow tract; SAM, Systolic anterior motion;
2D, Two-dimensional echocardiography.
exacerbate or induce these dynamic obstructions in cats with
HCM, which could cause hypotension, syncope, and exercise
intolerance. As such, some have described pimobendan as
contraindicated for use in animals with HCM despite the positive
clinical outcomes in the literature (13, 14).
Cats with HCM have a 28.3% risk of developing CHF,
making heart failure therapy an important part of HCM
disease management (15). In a previous retrospective case-
control study, pimobendan given to cats with HCM and CHF
provided a significant survival benefit of 523 days over cats
who did not receive pimobendan as a part of their treatment
(14). The etiology of this survival benefit remains unknown.
Beyond the inodilator properties of pimobendan, additional
pharmacodynamic effects have been reported in cats and other
species. Pimobendan improves diastolic function in dogs with
pacing-induced cardiomyopathy and humans with idiopathic
dilated cardiomyopathy (16, 17). A similar inodilator drug,
levosimendan, has also been shown to have positive lusitropic
effects perioperatively in humans with preserved ejection fraction
whowere receiving aortic valve replacements and coronary artery
bypass grafts (18, 19). Pimobendan has also been shown to
decrease left atrial (LA) size in normal cats, implying some
lusitropic or LA function benefit (20). These pharmacodynamic
qualities of the drug may represent the source of benefit for
cats with HCM and CHF, but to date, although many studies
have documented that pimobendan is well-tolerated in cats,
there have been no studies evaluating the pharmacodynamics of
pimobendan in cats with HCM (14, 21–26). Thus, it remains
unknown whether pimobendan could induce or exacerbate
dynamic LVOTOs, and whether any positive effects can be
documented in cats with HCM. This question translates to
similar questions in human cardiac disease, where the inodilator,
levosimandan has been shown to improve diastolic function
in patients with heart failure with preserved ejection fraction
(18, 19). As cats with HCM have recently been identified as an
animal model for heart failure with preserved ejection fraction,
elucidation of possible benefits in cats with HCM may also have
implications for similar cardiac diseases in humans (9, 27, 28).
We sought to assess the acute pharmacodynamic effects
of a single oral dose of pimobendan in cats with HCM
using echocardiography, with a specific aim to investigate
whether pimobendan could induce or exacerbate LVOTOs
Frontiers in Veterinary Science | www.frontiersin.org 2 February 2019 | Volume 6 | Article 15
Oldach et al. Pimobendan in Feline Hypertrophic Cardiomyopathy
in this population. We hypothesized that pimobendan
would not exacerbate LVOTOs. We also hypothesized that




All animal procedures were in accordance with the National
Research Council Guide for the Care and Use of Laboratory
Animals using protocols approved by the Institutional Animal
Care and Use Committee at the University of California, Davis.
Thirteen purpose-bred mixed-breed cats were used from a
research colony generated from a single Maine Coon/mixed-
breed founder cat with naturally occurring HCM due to a
variant in the myosin binding protein C gene (MYBPC). Six
of 13 cats were homozygous for the reported A31P MYBPC3
variant, while 5 were heterozygous for this variant and 2 wild
type for this variant and thus of unknown genetic etiology.
Cats were identified as affected by HCM if there was segmental
or diffuse interventricular or left ventricular posterior wall
thickness exceeding 6mm in the absence of hypertension or
hyperthyroidism on at least two serial examinations >1 month
apart, as identified on two-dimensional (2D) exam in the right
parasternal short-axis or long-axis view.






HR (mean bpm ± SD) 226 ± 31 231 ± 26 0.65
Thickest wall segment
[median mm (IQR)]
6.9 (6.6–7.1) 6.9 (6.7–7.1) 0.51
LAlax [median mm
(IQR)]
1.26 (1.2–1.4) 1.2 (1.1–1.6) 0.27
HR, heart rate; bpm, beats per minute; SD, standard deviation; IQR, interquartile range;
LAlax, maximal left atrial diameter.







LVOTO 11 12 1.00
SAM 4 5 1.00
Mid-LVOTO 10 11 1.00
DRVOTO 10 11 1.00
VPCs 3 3 1.00
SPCs 0 0 1.00
Adverse events 1 1 1.00
HCM 13 13 1.00
LVOTO, Left ventricular outflow tract obstruction; SAM, systolic anterior motion;
DRVOTO, dynamic right ventricular outflow tract obstruction; VPCs, ventricular
premature complexes; SPCs, supraventricular premature complexes; HCM, Hypertrophic
cardiomyopathy.
Experimental Design
The study was a randomized, double-blinded, cross-over
design. Lactulose powder (placebo) and 1.25mg pimobendan
tablets were placed into identical opaque capsules to facilitate
investigator blinding. The medications were randomized to
group A or B by a single unblinded individual not involved
in data acquisition or analysis. On their first evaluation
(exam 1), cats were randomized by coin-flip to receive either
medication A or B. One capsule of the assigned medication
was administered orally; 30min following the administration,
cats were sedated with acepromazine (0.5mg) and butorphanol
(1mg) administered intramuscularly in the epaxial muscles. One
hour after study medication administration, echocardiography
was performed. This time-frame was chosen based on a prior
pharmacokinetics study in cats, showing a predicted time to
peak plasma concentration of 54min (22). The cats were then
monitored for adverse effects, defined as any adverse event
occurring in temporal proximity to administration of the study
drug, including collapse, vomiting, diarrhea, agitation, ptyalism,
and arrhythmias. Arrhythmias were monitored for during the
echocardiogram by a lead II electrocardiographic rhythm strip.
After full recovery, the cats were returned to their colony housing.
At least 24 h after their initial examination, they were presented
for the crossover portion of the study, during which the same
procedure described above was performed with administration
of the opposite medication (i.e., cats who received medication
B during exam 1 received medication A on exam 2). Twenty-
four hours was deemed a sufficient wash-out period given that
it was >5 times the reported elimination half-life of pimobendan
(1.3 h) (22).








36.1 ± 6.0 41.7 ± 5.9 0.04
LVFS M-mode
(mean %, SD)
65.0 ± 13.6 68.3 ± 11.3 0.35
Mitral TDI S’
[median m/s (IQR)]
0.09 (0.08–0.11) 0.09 (0.08–0.10) 0.50
MAPSE (mean
mm, SD)
4.2 ± 0.7 3.8 ± 0.6 0.17
Auricular flow
(mean cm/s, SD)
90.6 ± 13.1 94.5 ± 12.7 0.44
TAPSE (mean mm,
SD)
8.3 ± 1.6 7.6 ± 1.6 0.10
IVRT (mean ms,
SD)
44.1 ± 11.8 46.2 ± 9.3 0.60
LVOT Vmax (mean
m/s, SD)
2.6 ± 1.0 2.8 ± 0.8 0.44
RVOT Vmax
(mean m/s, SD)
2.1 ± 0.9 2.2 ± 0.6 0.57
LAFS, left atrial fractional shortening; m-mode, motion mode; SD, standard deviation;
LVFS, Left ventricular fractional shortening,; TDI, tissue Doppler imaging; IQR, interquartile
range; MAPSE, mitral annular plane systolic excursion; TAPSE, tricuspid annular plane
systolic excursion, IVRT, isovolumetric relaxation time, LVOT Vmax, left ventricular outflow
tract maximal velocity; RVOT Vmax, Right ventricular outflow tract maximal velocity.
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Echocardiography
Thirty minutes after sedation with 1.0mg butorphanol
intramuscularly and 0.5mg acepromazine intramuscularly,
cats underwent echocardiographic exams. All echocardiographic
examinations were performed by a single investigator (MSO)
on a Phillips EPIQ CVx ultrasound machine using a 12 MHz
transducer with harmonics. Complete 2D, motion mode (m-
mode), color, and spectral Doppler echocardiography was
performed from standard imaging planes in right and left
lateral recumbency, as previously described (29); a concurrent
lead II continuous ECG was also recorded and monitored
for arrhythmias. Images were stored and measurements
were performed by a single investigator (MSO) at a remote
workstation using Siemens Syngo Dynamics proprietary
software.
Assessment of left ventricle (LV) hypertrophy was made
from 2D examination in right parasternal short axis or long
axis imaging using an inner edge to inner edge measurement
technique; segmental or diffuse interventricular or left ventricular
posterior wall thickness exceeding 6mm in the absence
of hypertension or hyperthyroidism on at least two serial
examinations >1 month apart was considered consistent with
HCM. Dynamic right ventricular outflow tract obstruction
(DRVOTO) was identified from the right parasternal short axis
view, andwas defined as the presence of color Doppler turbulence
within the proximal infundibular region of the right ventricular
outflow tract (RVOT), with a spectral continuous wave Doppler
velocity >1.6 m/s, in the absence of other cardiac pathology (i.e.,
cardiac shunting lesions or pulmonic stenosis, as this velocity
exceeds the upper limits of normal RVOT velocity (30). LVOTO
was identified from the left parasternal 5-chamber view, and was
defined as the presence of color Doppler flow turbulence in the
left ventricular outflow tract (LVOT) and a late-peaking spectral
continuous wave Doppler signal with a velocity of >1.9 m/s, the
upper end of normal LVOT velocity (30). The cursor was aligned
with the color Doppler turbulent flow, and the maximal modal
velocity obtained was recorded. Mid LVOTO was identified
when there was mid-ventricular hypertrophy with color flow
turbulence arising in the mid LV during systole in combination
with the spectral Doppler features mentioned previously. The
presence or absence of SAM was also noted based on 2D exam.
Additional echo measurements were acquired as follows:
left atrial fractional shortening (LAFS) with m-mode in the
right parasternal short axis view (31); LV fractional shortening
with m-mode from the right parasternal short axis view; 2D
left atrial to aortic ratio from the right parasternal short axis
view; the maximal left atrial diameter in 2D from the right
parasternal long-axis view; pulsed wave tissue Doppler imaging
of the lateral mitral annulus S’ wave from the left apical 4-
chamber view; m-mode mitral annular plane systolic excursion
of the septal annulus from the left apical 4-chamber view; LV
isovolumetric relaxation time using spectral pulsed wave Doppler
from the left parasternal 4-chamber view; tricuspid annular plane
systolic excursion from the left parasternal apical 4-chamber view
optimized for the RV; spectral pulsed wave Doppler left auricular
flow velocity from the left parasternal cranial long axis view
optimized for the left auricle. Transmitral spectral Doppler and
diastolic tissue Doppler imaging was attempted from the left
apical 4-chamber view, but was unsuccessful due to persistent
tachycardia resulting in fusion of the early and late filling
waves.
Statistics
Statistical analysis was performed using GraphPad Prism version
7.0 and GraphPad Quickcalcs. (GraphPadSoftware Inc., La Jolla,
CA, USA). All variables were first analyzed for column statistics
and tested for normality by visual inspection and D’Agostino
Pearson Omnibus Normality test. Normally distributed data are
reported as mean± standard deviation. Non-parametric data are
reported as median and interquartile range. Group A vs. group
B statistical comparisons were performed for paired data using a
paired t-test (when normally distributed) and aWilcoxon signed-
rank matched pairs test (when non-parametric). Categorical
variables were coded as 0 (no) and 1 (yes) to create a 2 × 2
contingency table for the purposes of statistical analysis. These
variables were tested for significant differences between groups
A and B using a Fisher’s exact test. Correlations between LVOT
maximal velocity and heart rate (HR) at the time of measured
velocity as well as RVOT maximal velocity and HR at the time
of measured velocity were evaluated using a Pearson Correlation
Coefficient. A p < 0.05 was considered significant. When values
were missing on some cats, the corresponding value in the cross-
over group was deleted to permit continuation of paired sample
testing. In the case where values were unavailable, the number of
animals included in the paired sample analysis is reported (n=x).
Categorical variables were coded as 0 (no) and 1 (yes) to create
a 2 × 2 contingency table for the purposes of statistical analysis.
These variables were tested for significant differences between
groups A and B using a Fisher’s exact test through Graphpad
QuickCalcs (GraphPadSoftware Inc., La Jolla, CA, USA).
RESULTS
Thirteen purpose-bred mixed-breed cats were included in the
study. Median age of the cats was 50 months (range 12–83
months). All cats had a maximal segmental or uniform wall
thickness of >6mm in both treatment groups. All cats had
systolic heart murmurs at both examinations, with a median
murmur grade of IV/VI in both treatment groups and a range of
II-IV/VI.Murmur grades were not significantly different between
groups (p > 0.9999). There was no significant difference in HR,
LA size, and segmental wall thickness between the two treatment
groups (Table 1).
There were no significant differences between the number
of cats in each group with SAM, LVOTO, or mid-LVOTO
(Table 2). Eleven cats in the placebo group had an LVOTO;
10 of these cats had a mid-LVOTO and 4 had SAM. Twelve
cats in the pimobendan treatment group had LVOTO, with 11
experiencing mid-LVOTO and 5 with SAM. One cat without
SAM in the placebo group had documented SAM in the
pimobendan group; no cats without SAM in the pimobendan
group had documented SAM in the placebo group. Ten cats in
the placebo and 11 cats in the pimobendan group had DRVOTO;
this number was not significantly different between groups
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FIGURE 1 | (A) A paired t-test comparison of maximal left ventricular outflow tract velocity (LVOT Vmax) (m/sec) between cats receiving placebo and pimobendan is
shown. No significant differences were identified (P = 0.44). A dashed line represents the threshold considered to constitute left ventricular outflow tract obstruction in
this study at 1.9 m/s. (B) A paired t-test comparison of maximal right ventricular outflow tract velocity (RVOT Vmax) (m/sec) between cats receiving placebo and
pimobendan is shown. No significant differences were identified (P = 0.57). A dashed line represents the threshold considered to constitute right ventricular outflow
tract obstruction in this study at 1.6 m/s.
FIGURE 2 | (A) A paired t-test comparison of left atrial (LA) fractional shortening (%) measured by m-mode between cats receiving placebo and pimobendan is
shown. Cats receiving pimobendan had significantly increased left atrial fractional shortening (P = 0.04). (B) A paired t-test comparison of left auricular flow velocity
(cm/sec) measured by spectral Doppler between cats receiving placebo and pimobendan is shown. No significant differences were identified (P = 0.44).
(Table 2). The LVOT and RVOT velocities in the treatment and
placebo group did not differ significantly (Table 3; Figure 1).
The median LVOT velocity in the placebo group was 2.66 m/s
with a range of 0.82–4.05 m/s; the median LVOT velocity in the
treatment group was 2.84 m/s with a range of 1.31–4.55 m/s
(Figure 1).
Functional echocardiographic values are presented in
Table 3. Left atrial fractional shortening in the pimobendan
treatment group was significantly greater than the placebo
group (Figure 2A), however no differences in left auricular flow
velocity were identified (Figure 2B). There were no significant
differences in LV fractional shortening, mitral annulus tissue
Doppler imaging S’, or mitral annular plane systolic excursion
M-mode (Figure 3).
No significant correlations were observed between LVOT
maximal velocity and HR in the pimobendan group (r = 0.35,
p = 0.24), or in the placebo group (r = 0.30 p = 0.32). No
significant correlations were observed between RVOT maximal
velocity and HR in the pimobendan group (r = −0.27, p = 0.37)
or the placebo group (r = 0.49, p= 0.09).
There was no significant difference in the prevalence
of ventricular arrhythmias between groups (Table 2). No
supraventricular ectopy was noted in either group.
One cat from each group experienced an adverse event
during the evaluation. There was no difference in the number
of adverse events between groups (Table 2). One of these cats in
the pimobendan group experienced transient bradycardia (125
bpm) and brief loss of postural tone during the examination.
This patient demonstrated a notable stress response (HR > 300
bpm) despite sedation and this episode was considered likely
pre-syncope. This cat did not experience a new obstruction
with tachycardia. The placebo measured LVOT velocity for this
cat was 4.05 m/s and was mildly increased to 4.55 m/s after
pimobendan and this patient was observed to have both SAM
andmid-LVOTO at both evaluations. Additionally, one cat in the
placebo group experienced diarrhea upon the conclusion of the
exam.
DISCUSSION
This study demonstrated that pimobendan has a positive effect
on LA function, as shown by an increase in the LAFS m-mode,
which was significantly increased compared with the placebo
group. This finding could explain some of the survival benefit
that has been documented in HCM cats with CHF receiving
pimobendan (14). Prior studies have shown reduced LAFS in
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HCM cats with CHF, with these cats also having an increased
risk for thromboembolic disease and death (31, 32). Similarly, an
increased risk of thromboembolic disease in cats with reduced
auricular flow velocities, another measure of LA function, has
also been demonstrated (32). Improved LA function would
improve LV filling and limit LA dilation, which may help prevent
thromboembolic complications and improve CHF control.
It is interesting that although LAFS m-mode increased in the
pimobendan group, the LV internal dimension in diastole did
not increase, as an increase in LA emptying should improve
LV filling and thus increase LV diastolic dimension. This
discrepancy is most likely related to the challenges of accurate
LV measurement in cats with tachycardia and irregular LV
concentric hypertrophy. Persistent tachycardia likely limited
imaging resolution, potentiating measurement error. In addition,
many cats had asymmetric hypertrophy of their left ventricles,
and identical imaging planes may not have been achieved
between studies. Future clinical studies may benefit from
selecting compliant patients where less significant tachycardia
and better cooperation without the necessity for sedation may
help circumvent this potential issue.
Despite showing a significant benefit in LAFS m-mode, this
study did not show a significant change in LA size, which was
shown in a previous study of apparently healthy cats (20). This
discrepancymay be due to differences in duration of pimobendan
administration, with the cats in the aforementioned study
receiving pimobendan for 7 days vs. single-dose administration
in the present study (20). Alternatively, myocardial stiffening
and diastolic dysfunction present in HCM cats may prevent the
degree of LA size reduction that may be possible in normal
cats with normal LV compliance. This same study did not show
increases in LAFS, unlike our study (20).
Another LA function measure, auricular flow velocity, was
not significantly different between treatment groups in this
study. This is consistent with prior research in normal cats,
suggesting that although pimobendan increases the degree of LA
contraction, it may not affect the speed of LA contraction (20).
However, it is possible that pimobendan may have effects on
auricular flow velocity in cats with significant LA enlargement
and remodeling or the setting of preexisting reduced auricular
flow, which was not present in this study population and should
be evaluated in future studies.
This study did not show evidence of exacerbation of
LVOTO with pimobendan, which has been a major theoretical
concern in administration of this drug to cats. There was
no significant difference in LVOT velocities between the
treatment groups. However, given individual anatomic variation
in HCM disease manifestation, consideration of individual
cats is prudent. There was one cat that developed SAM
after pimobendan administration; this cat received pimobendan
on the second study evaluation day. Thus, an increase
in sympathetic tone associated with the second day of
handling cannot be distinguished from a pimobendan drug
effect. Additionally, one cat developed mid LVOTO following
pimobendan administration, with LVOT velocity increasing from
0.82 m/s up to 3.25 m/s despite receiving pimobendan on
the first examination. However, it is important to note that
FIGURE 3 | (A) A paired t-test comparison of left ventricular fractional
shortening (%) measured by m-mode between cats receiving placebo and
pimobendan is shown. No significant differences were identified (P = 0.35).
(B) A Wilcoxon matched-pairs signed rank test comparison of lateral mitral
annulus tissue Doppler imaging (TDI) S’ wave (m/sec) between cats receiving
placebo and pimobendan is shown. No significant differences were identified
(P = 0.58). (C) A paired t-test comparison of septal mitral annular plane
systolic excursion (MAPSE) (mm) measured by m-mode between cats
receiving placebo and pimobendan is shown. No significant differences were
identified (P = 0.17).
this cat’s HR was higher at the peak LVOT velocity after
pimobendan (294 bpm) than after placebo (232 bpm), which
may demonstrate more of a HR-dependent effect on LVOTO
rather than a direct pimobendan drug effect. This is corroborated
by the observable dynamic nature of SAM and LVOTO in cats.
Finally, one cat experienced a suspected pre-syncopal episode
during the examination. This cat had SAM and mid LVOTO,
but the LVOT velocity was only mildly increased following
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pimobendan (4.55 vs. 4.05 m/s). A direct drug effect again
cannot be definitively determined, as sympathetic surge during
the examination could also have contributed to the pre-syncopal
event, given the patient was particularly fractious. Further studies
evaluating other cardiovascular effects of pimobendan, such as
blood pressure, in HCM cats are necessary.
Similar to a previous study, we did not identify any observable
increase in systolic function at our single time point evaluation
(21). In order to identify any impact on systolic function, the
prior study averaged effects over multiple evaluations 12 h post-
pimobendan administration (20). In the present study, only acute
effects were evaluated. This leads us to agree with prior research
that the systolic function effects of pimobendan, particularly in
the acute setting are either clinically irrelevant or non-existent.
The lack of identifiable changes may be due to the presence of
HCM pathology in conjunction with marked sympathetic tone
of the cats in this study. The cats likely reached a physiologic
maximum in systolic function, thus limiting the ability to identify
differences between treatment groups; in addition, several cats
experienced end-systolic cavity obliteration, which may have
contributed to measurement error. This is a challenge inherent
to feline research. Future studies may aim to enroll study subjects
amenable to handling so as to limit confounding effects of
elevated sympathetic tone.
Diastolic function assessment was largely precluded by
persistent tachycardia in the cats. Thus, the diastolic function
benefits previously demonstrated in dogs and humans could not
be explored in these cats (16, 17). Future studies with larger
sample sizes or invasive assessments of LV pressure volume
relationships may help elucidate diastolic function effects of
pimobendan in cats.
The study was limited by the fact that the time to peak
physiologic drug effects of pimobendan in cats remains unknown
(21). Although the time to peak plasma concentration has
been identified and was used in this study as a surrogate
for peak physiologic effect, the peak plasma concentration
does not necessarily correlate with peak drug effects. Studies
involving more long-term administration of pimobendan may
help to better characterize pharmacodynamics of the drug in
cats with HCM. Additionally, the persistent tachycardia and
high sympathetic tone of the study population likely limited
the precision of echocardiographic measurements, making
it difficult to identify small differences between treatment
groups given the small sample size. Another limitation lies
in imperfections of spectral Doppler studies since accurate
measurement of LVOT velocity requires parallel alignment
with the fastest blood flow stream. Although the outflow
tract was scanned from multiple angles, with only the fastest
flow velocity recorded, it is possible that some velocities
are underestimated due to suboptimal alignment. Although
the plane of sedation was minimal and sedation may be
necessary in clinical feline patients, this could have minimally
impacted cardiac function and our results. Finally, the scope
of echocardiographic measures assessed in this study were
somewhat limited and more advanced echocardiographic
assessment of cardiac function or perhaps invasive hemodynamic
assessment of cardiac function could represent future study
opportunities.
In conclusion, the present study suggests that pimobendan
imparts a significant benefit in LA function in cats with HCM
and provides evidence that pimobendan does not significantly
increase systolic function and LVOT obstructions. The drug
appears to be well-tolerated in this group of cats, although the
pre-syncopal event experienced by one cat after pimobendan
cannot be ruled out as an adverse event directly related to
pimobendan. Further studies with longer-term administration of
pimobendan to unsedated, compliant cats are indicated to better
characterize its safety and physiologic effects and translate these
effects to clinical applications.
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